2910 Seventh Street
United States - Map
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companys lead product candidate includes gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçets disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, as well as diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. Its proprietary product pipeline also comprises XOMA metabolic activating, sensitizing, and deactivating/antagonizing antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, the company licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has collaboration and licensing agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; Symplmed Pharmaceuticals, LLC; and Texas A&M University. The company was founded in 1981 and is headquartered in Berkeley, California.
|XOMA Corporation’s ISS Governance QuickScore as of Oct 1, 2015 is 6. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 2; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John W. Varian ,
Chief Exec. Officer and Director
|Mr. Patrick J. Scannon M.D., Ph.D.,
Founder, Chief Scientific Officer, Exec. VP and Director
|Mr. Paul D. Rubin M.D.,
Chief Medical Officer and Sr. VP of R&D
|Mr. Thomas Burns ,
Chief Financial Officer and VP of Fin.
|Mr. James R. Neal ,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|